NeuTec Pharma   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Istanbul Turkey (1992)
Status: Defunct (2010)

Organization Overview

First Clinical Trial
2004
NCT00217841
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Neutec Ar-Ge Clinical Trial | Neutec Ar-Ge San ve Tic A.Ş | Neutec Ar-Ge San ve Tic A.S Clinical Trial | NeuTec Pharma | Project Consultant

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Bronchitis (Phase 4)

Bronchitis, Chronic (Phase 4)

Communicable Diseases (Phase 3)

Erectile Dysfunction (Phase 4)

Gastroesophageal Reflux (Phase 4)

Hypertension (Phase 4)

Infections (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pneumonia (Phase 4)

Premature Birth (Phase 4)

Premature Ejaculation (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Respiratory Aspiration (Phase 4)

Sinusitis (Phase 3)

Staphylococcal Infections (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 25